Latest news with #antibody
Yahoo
2 days ago
- Business
- Yahoo
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit/CAFC issued a Rule 36 Order, which affirmed the validity of its US Patent No. 10,087,408 ('the '408 Patent'). The patent specifically covers microfluidic devices and their application in culturing and selectively recovering cells. Previously, Bruker Cellular Analysis Inc., which is a subsidiary of Bruker Corporation (NASDAQ:BRKR), had challenged the claims of the '408 Patent. Bruker argued for the patent's invalidity based on allegations of anticipation and obviousness in light of prior art. However, the US Patent Trial and Appeal Board/PTAB rejected all of Bruker's arguments. The CAFC's recent decision further confirms the validity of all claims within AbCellera's '408 Patent. A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. The 408 Patent is an integral part of ongoing multi-patent infringement litigation between AbCellera and Bruker, which is currently pending in the US District Court for the Northern District of California. AbCellera intends to continue defending its intellectual property portfolio and looks forward to proving its infringement case against Bruker in the District Court. AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US. Bruker Corporation (NASDAQ:BRKR) develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17-06-2025
- Business
- Yahoo
Antibody Collaboration and Licensing Agreements Analysis Report 2025 with Directory of Deals - Upfront, Milestone, Royalties Financial Terms, Company A-Z, Deal Type and Therapy Area
Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the world's leading biopharma companies. This report contains a comprehensive listing of 1486 antibody deals announced since 2019 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their revised and updated, the report provides details of antibody deals from 2019 to 2025. The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of antibody 1 provides an introduction to the 2 provides an overview of the trends in antibody dealmaking since 3 provides an overview of the leading antibody deals since 2019. Deals are listed by headline 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2019, where a contract document is available in the public 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific antibody technology type in report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2019 Browse antibody collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Antibody Collaboration and Licensing Deals includes: Trends in antibody dealmaking in the biopharma industry Directory of antibody deal records covering pharmaceutical and biotechnology The leading antibody deals by value Most active antibody licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in antibody dealmaking2.1. Introduction2.2. Antibody deals over the years2.3. Most active antibody dealmakers2.4. Antibody deals by deal type2.5. Antibody deals by therapy area2.6. Antibody deals by industry sector2.7. Deal terms for antibody deals2.7.1 Antibody deals headline values2.7.2 Antibody deal upfront payments2.7.3 Antibody deal milestone payments2.7.4 Antibody royalty ratesChapter 3 - Leading antibody deals3.1. Introduction3.2. Top antibody deals by valueChapter 4 - Most active antibody dealmakers4.1. Introduction4.2. Most active antibody dealmakers4.3. Most active antibody deals company profilesChapter 5 - Antibody contracts dealmaking directory5.1. Introduction5.2. Antibody contracts dealmaking directoryChapter 6 - Antibody dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
09-06-2025
- Health
- Reuters
US FDA approves Merck's RSV antibody for infants
June 9 (Reuters) - The U.S. Food and Drug Administration on Monday approved Merck's (MRK.N), opens new tab preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.
National Post
05-06-2025
- Business
- National Post
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Article content BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. Article content RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. Article content With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. Article content With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. Article content About Biocytogen Article content Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit Article content Article content Article content Contacts Article content Biocytogen Contacts Article content Article content Antibody assets and platforms: Article content Article content Article content
Yahoo
24-05-2025
- Health
- Yahoo
OSU researchers create nasal spray that could stop the flu; blocks infection in mice
An antibody that could revolutionize the prevention of influenza, other viruses and even non-viral diseases like cancer was recently engineered by Ohio State scientists. In a study published April 29, this new molecule was successful in protecting a majority of the tested mice from lethal flu doses, even preventing some from experiencing any symptoms at all, according to a May 8 Ohio State News article. Head researcher and the study's co-lead author Dr. Kai Xu said the engineered molecule — transmitted via nasal spray — works by triggering 'mucosal immunity,' meaning it coats the tissue that lines the body's organs and tracts before a virus can enter. By contrast, current flu vaccines rely on 'systemic immunity,' which fights the virus after infection. Xu said combining both immune responses into one engineered antibody could 'enhance the protection' of conventional, injection-based vaccines. 'Our creation can complement the conventional vaccine in terms of targeting to prevent the seasonal flu infection,' Xu, also an Ohio State assistant professor of veterinary biosciences, said. 'It can be a replacement, but we believe that these two can synergize with each other.' Researchers created the new antibody by combining two existing ones: immunoglobulin G, which makes up most antibodies in the human body and has two 'arms' to target specific viruses, and immunoglobulin M, the immune system's first line of defense with 10 'arms' to attack infection. Traditionally, flu prevention has focused on IgG. The problem, Xu said, is that the flu virus can mutate, making it harder for IgG to identify and fight it. IgM, however, can still latch onto the virus even if a part of it changes, thanks to its many arms. By combining IgM's 'stickiness' with IgG's precision, Xu said his lab engineered an antibody that could neutralize the flu more effectively than either antibody alone. When tested on mice using a nasal spray, Xu said the antibody successfully stuck to their mucosal surfaces for a week, protecting most from lethal doses of common flu strains. Xu said this finding suggests the antibody could work similarly in humans. If used to complement existing flu vaccines, the engineered antibody would be especially beneficial not only in years when medical professionals inaccurately predict the specific strain that spreads during flu season, but also for individuals who don't have a strong immune response to vaccines, Xu said. Since this study was published, Xu said his team has continued its analysis to work toward a large-animal experiment — which is necessary before a clinical trial can take place — and optimizing the molecule's production so large amounts can be obtained quickly for further testing. Xu said his team is also working on expanding the scope of this study to other kinds of illness beyond influenza — from bird flu to cancer to coronavirus. By working with other research programs at Ohio State and pharmaceutical company IGM Biosciences, Xu said he hopes his team's research can one day become a therapeutic drug. 'This research really benefits from multidisciplinary collaboration,' Xu said. 'I think that by enhancing the collaboration within OSU and even with the industry partner in the future, we will certainly enhance our research for a national medicine.' Reporter Emma Wozniak can be reached at ewozniak@ or @emma_wozniak_ on X, formerly known as Twitter. This article originally appeared on The Columbus Dispatch: OSU study finds new antibody to prevent the flu through nasal spray
